The 2025 ASCO Annual Meeting may not have delivered the dramatic, headline-making breakthroughs of previous years, but for commercial teams in pharmaceuticals and biotechnology, it offered something far more valuable: a clear signal of where oncology is heading - and what it will take to stay competitive.
Precision medicine is no longer a future ambition. It’s the present reality. And ASCO 2025 confirmed that the commercial success of oncology therapies now hinges on how well companies can navigate a rapidly evolving diagnostic and data ecosystem.
Drawing on their expert analysis and firsthand experience at ASCO 2025, Susanne Munksted and Kevin Entwistle identify five key trends that emerged from this year’s meeting - and what they mean for your commercial strategy.
Want the full breakdown? Watch the 30-minute session here
👉 Watch Now: Fresh from ASCO 2025: What recent oncology advancements mean for your commercial strategy
Precision medicine is now the standard
The language of precision medicine has become mainstream. Biomarkers are now discussed with the same frequency and weight as traditional endpoints like progression-free survival (PFS) and overall survival (OS). This shift reflects a broader industry transformation: precision medicine is no longer a specialized niche - it’s the foundation of modern oncology.
The industry’s understanding of precision medicine has evolved. It’s now focused on action - on what we can do to move the needle.
— Kevin Entwistle, VP of Precision Medicine Strategy, Diaceutics
For commercial teams, this means that every launch strategy must now include a diagnostic strategy. From awareness, availability and adoption to access and action, the entire patient journey must be mapped with precision in mind.
Data trends powering oncology progress
While ASCO 2025 lacked the dramatic data reveals of years past, it delivered a steady stream of meaningful clinical insights. Trials like SERENA-6, MATTERHORN, and AMPLITUDE may not have made headlines, but they are certainly reshaping treatment paradigms in breast, colon, and prostate cancers.
These studies signal a shift in testing requirements, treatment sequencing, or biomarker-driven stratification - all of which have direct implications for market access, physician education, and patient identification. Importantly, these insights are signalling a broader shift in oncology where patients can access life-changing therapies earlier in their disease course - potentially improving outcomes and redefining standards of care.
The ACD pipeline is surging, and diagnostics must keep up
Antibody-drug conjugates (ADCs) were a major focus at ASCO 2025, with new agents targeting HER2, HER3, DLL3, SEZ6, and Nectin-4. This explosion of innovation is exciting - but it also introduces significant complexity.
Each new ADC often requires a specific immunohistochemistry (IHC) test, with unique clones, cutoffs, and scoring algorithms. This creates a fragmented diagnostic landscape that can slow adoption and confuse clinicians.
We’re seeing a repeat of the PD-L1 scenario - different drugs, different clones, different scoring algorithms. Accuracy and concordance are critical.
— Kevin Entwistle
For commercial teams, the takeaway is clear: diagnostic readiness must be built into launch planning from day one. That includes partnerships with diagnostic developers, education for pathologists, and strategies to ensure tissue availability and test standardization.
ctDNA and MRD are moving from research to routine
Circulating tumor DNA (ctDNA) and minimal residual disease (MRD) detection are no longer emerging technologies - they are becoming essential tools in oncology care. ASCO 2025 featured compelling data from studies like MONSTAR-SCREEN-3 and DYNAMIC-III, demonstrating ctDNA’s ability to guide adjuvant therapy, monitor treatment response, and predict recurrence.
This is no longer just a research tool. ctDNA is informing real-world treatment decisions - and commercial teams need to plan accordingly.
— Susanne Munksted, Chief Precision Medicine Officer, Diaceutics
The implications are significant. Pharma companies must now make smarter, more holistic decisions during clinical development-decisions that proactively lay the groundwork for global ctDNA testing availability at launch.
Digital pathology is driving demand for scalable infrastructure for routine clinical adoption
Computational pathology and AI were once seen as futuristic add-ons. Today, they are becoming essential components of diagnostic workflows - particularly in the context of complex biomarkers and limited tissue availability.
ASCO 2025 showcased how AI is being used to interpret IHC stains, predict biomarker status from H&E slides, and support pathologists in identifying patients for targeted therapies. In some cases, AI is the only viable method for detecting certain biomarkers, making it a gatekeeper for therapy access.
We’re approaching an inflection point. These tools are no longer optional - they’re essential to enabling access to targeted therapies.
— Kevin Entwistle
For commercial teams, this means thinking beyond the drug and beyond the test itself. It means planning for the enabling technologies-like scanning, digitization, and cloud-based platforms-that make AI-enabled diagnostics possible at scale.
What this means for commercial strategy
ASCO 2025 confirmed that the future of oncology is precision-driven, diagnostics-enabled, and data-powered. For commercial and medical affairs teams, this means:
- Investing early in diagnostic strategy - including test development, access, and education.
- Collaborating with diagnostic partners to build globally scalable, launch-ready infrastructure, not just U.S.-centric solutions.
- Laying the groundwork for AI and digital pathology by addressing the infrastructure gaps that limit routine clinical adoption.
- Translating clinical insights into action - not just for physicians, but across the entire commercial ecosystem.
Interested to discuss this with our experts? Book a call here.
